Therapeutic Asset Ratings

247 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Ivonescimab Colorectal Liver Metastases	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Mitoxantrone Adolescents	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Mitoxantrone Children	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Osimertinib Disitamab Vedotin	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Osimertinib ERBB2 Gene Duplication	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Osimertinib ERBB2 Mutation-Related Tumors	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Pembrolizumab Tumor Thrombosis	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Pyrotinib Disitamab Vedotin	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Pyrotinib ERBB2 Gene Duplication	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Pyrotinib ERBB2 Mutation-Related Tumors	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
rc48-adc Disitamab Vedotin	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
rc48-adc ERBB2 Gene Duplication	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
rc48-adc ERBB2 Mutation-Related Tumors	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Romiplostim Adolescent	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Romiplostim Children	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Telpegfilgrastim Adolescent	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Telpegfilgrastim Neutropenia	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Telpegfilgrastim Children	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Tislelizumab Capecitabine	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Tislelizumab First-Line	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Tislelizumab MSS/pMMR	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Tislelizumab Oxaliplatin	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Tislelizumab RAS-mutated	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Toripalimab Peripheral T-Cell Lymphoma, Not Otherwise Specified	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Tucidinostat Targeted Therapy	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)

Showing 101 to 125 of 247 assets

PreviousPage 5 of 10Next